Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 1
2019 3
2020 1
2021 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Bayes-based dosing of infliximab in inflammatory bowel diseases: Short-term efficacy.
Santacana Juncosa E, Rodríguez-Alonso L, Padullés Zamora A, Guardiola J, Rodríguez-Moranta F, Serra Nilsson K, Bas Minguet J, Morandeira Rego F, Colom Codina H, Padullés Zamora N. Santacana Juncosa E, et al. Among authors: padulles zamora a. Br J Clin Pharmacol. 2021 Feb;87(2):494-505. doi: 10.1111/bcp.14410. Epub 2020 Jun 26. Br J Clin Pharmacol. 2021. PMID: 32495380 Free article.
Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
Padullés Zamora A, Juvany Roig R, Leiva Badosa E, Sabater Riera J, Pérez Fernández XL, Cárdenas Campos P, Rigo Bonin R, Alía Ramos P, Tubau Quintano F, Sospedra Martinez E, Colom Codina H. Padullés Zamora A, et al. J Antimicrob Chemother. 2019 Oct 1;74(10):2979-2983. doi: 10.1093/jac/dkz299. J Antimicrob Chemother. 2019. PMID: 31335959
[Individualized infliximab therapy: pharmacokinetic monitoring].
Santacana-Juncosa E, Padullés-Zamora A, Colom Codina H, Rodríguez-Alonso L, Guardiola-Capon J, Padullés-Zamora N. Santacana-Juncosa E, et al. Among authors: padulles zamora a. Farm Hosp. 2015 Jan 1;39(1):59-60. doi: 10.7399/fh.2015.39.1.7791. Farm Hosp. 2015. PMID: 25680435 Free article. Spanish. No abstract available.
Predictive Factors of Piperacillin Exposure and the Impact on Target Attainment after Continuous Infusion Administration to Critically Ill Patients.
Martínez-Casanova J, Esteve-Pitarch E, Colom-Codina H, Gumucio-Sanguino VD, Cobo-Sacristán S, Shaw E, Maisterra-Santos K, Sabater-Riera J, Pérez-Fernandez XL, Rigo-Bonnin R, Tubau-Quintano F, Carratalà J, Padullés-Zamora A. Martínez-Casanova J, et al. Among authors: padulles zamora a. Antibiotics (Basel). 2023 Mar 7;12(3):531. doi: 10.3390/antibiotics12030531. Antibiotics (Basel). 2023. PMID: 36978398 Free PMC article.
Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?
Esteve-Pitarch E, Gumucio-Sanguino VD, Cobo-Sacristán S, Shaw E, Maisterra-Santos K, Sabater-Riera J, Pérez-Fernandez XL, Rigo-Bonnin R, Tubau-Quintano F, Carratalà J, Colom-Codina H, Padullés-Zamora A. Esteve-Pitarch E, et al. Among authors: padulles zamora a. Eur J Drug Metab Pharmacokinet. 2021 Jul;46(4):527-538. doi: 10.1007/s13318-021-00694-0. Epub 2021 Jun 15. Eur J Drug Metab Pharmacokinet. 2021. PMID: 34131869
Is there a difficulty in maintaining haemoglobin target levels in pre-dialysis patients treated with erythropoiesis-stimulating agents?
Santacana-Juncosa E, Padullés-Zamora N, Padullés-Zamora A, Comas-Sugrañes D, Santulario-Verdú L, Sanmartí-Martínez N, Martínez-Castelao A. Santacana-Juncosa E, et al. Among authors: padulles zamora a. Nefrologia. 2014;34(2):263-4. doi: 10.3265/Nefrologia.pre2013.Dec.12312. Nefrologia. 2014. PMID: 24658202 Free article. English, Spanish. No abstract available.